JP2014526475A - がん幹細胞を含む幹細胞の増殖、進展、または分化の阻害のためのHs.459642ユニジーンクラスター産物のアンタゴニスト - Google Patents
がん幹細胞を含む幹細胞の増殖、進展、または分化の阻害のためのHs.459642ユニジーンクラスター産物のアンタゴニスト Download PDFInfo
- Publication number
- JP2014526475A JP2014526475A JP2014529965A JP2014529965A JP2014526475A JP 2014526475 A JP2014526475 A JP 2014526475A JP 2014529965 A JP2014529965 A JP 2014529965A JP 2014529965 A JP2014529965 A JP 2014529965A JP 2014526475 A JP2014526475 A JP 2014526475A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- unigene cluster
- stem cells
- cells
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (22)
- それを必要としている患者において、幹細胞またはがん幹細胞の増殖、分化、または進展を阻害する方法であって、治療有効量のHs.459642ユニジーンクラスター産物のアンタゴニストを前記患者に投与することを含む、方法。
- 前記アンタゴニストが、1つまたは複数の追加の抗がん治療と併用して投与される、請求項1に記載の方法。
- 追加の抗がん治療が、手術、放射線療法、または化学療法剤の投与である、請求項2に記載の方法。
- Hs.459642ユニジーンクラスター産物のアンタゴニストが、追加の抗がん治療より前に投与される、請求項2に記載の方法。
- Hs.459642ユニジーンクラスター産物のアンタゴニストおよび追加の抗がん治療が同時に施行される、請求項2に記載の方法。
- Hs.459642ユニジーンクラスター産物のアンタゴニストがHs.459642ユニジーンクラスター産物特異的抗体である、請求項2に記載の方法。
- Hs.459642ユニジーンクラスター産物特異的抗体がポリクローナルまたはモノクローナルである、請求項6に記載の方法。
- Hs.459642ユニジーンクラスター産物特異的抗体が完全または部分的ヒト化モノクローナル抗体である、請求項7に記載の方法。
- アンタゴニストがアンチセンスオリゴヌクレオチドアンタゴニストである、請求項1に記載の方法。
- Hs.459642ユニジーンクラスター産物がCACNA1Hである、請求項1〜9のいずれか一項に記載の方法。
- 幹細胞およびがん幹細胞の増殖、分化、または進展を阻害する、Hs.459642ユニジーンクラスター産物の活性のアンタゴニストを含む薬理学的組成物。
- アンタゴニストが、Hs.459642ユニジーンクラスター産物をアンタゴナイズする抗体である、請求項11に記載の組成物。
- 抗体がポリクローナルまたはモノクローナルである、請求項12に記載の組成物。
- 抗体が完全または部分的ヒト化モノクローナル抗体である、請求項14に記載の組成物。
- アンタゴニストがアンチセンスオリゴヌクレオチドアンタゴニストである、請求項11に記載の組成物。
- Hs.459642ユニジーンクラスター産物がCACNA1Hである、請求項11〜15のいずれか一項に記載の組成物。
- Hs.459642ユニジーンクラスター産物をアンタゴナイズする抗体。
- ポリクローナルまたはモノクローナルである、請求項17に記載の抗体。
- 完全または部分的ヒト化モノクローナル抗体である、請求項18に記載の抗体。
- Hs.459642ユニジーンクラスター産物がCACNA1Hである、請求項17〜19のいずれか一項に記載の抗体。
- Hs.459642ユニジーンクラスター産物をアンタゴナイズするアンチセンスオリゴヌクレオチド。
- Hs.459642ユニジーンクラスター産物がCACNA1Hである、請求項21に記載のアンチセンスオリゴヌクレオチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161533545P | 2011-09-12 | 2011-09-12 | |
US61/533,545 | 2011-09-12 | ||
PCT/US2012/054567 WO2013039859A1 (en) | 2011-09-12 | 2012-09-11 | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014526475A true JP2014526475A (ja) | 2014-10-06 |
JP2014526475A5 JP2014526475A5 (ja) | 2015-11-05 |
Family
ID=47830014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014529965A Pending JP2014526475A (ja) | 2011-09-12 | 2012-09-11 | がん幹細胞を含む幹細胞の増殖、進展、または分化の阻害のためのHs.459642ユニジーンクラスター産物のアンタゴニスト |
Country Status (12)
Country | Link |
---|---|
US (2) | US20130064814A1 (ja) |
EP (1) | EP2755674A4 (ja) |
JP (1) | JP2014526475A (ja) |
KR (1) | KR20140084034A (ja) |
CN (1) | CN103957923B (ja) |
AU (1) | AU2012309800B2 (ja) |
CA (1) | CA2848311A1 (ja) |
HK (1) | HK1200120A1 (ja) |
IL (1) | IL231385A0 (ja) |
MX (1) | MX2014002967A (ja) |
SG (2) | SG10201601917XA (ja) |
WO (1) | WO2013039859A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017195882A (ja) * | 2016-04-25 | 2017-11-02 | クラシエホールディングス株式会社 | 未分化細胞除去剤 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX360640B (es) | 2010-03-01 | 2018-11-09 | Tau Therapeutics Llc Star | Diagnosis e imagenologia de cancer. |
JP2017031059A (ja) | 2014-01-29 | 2017-02-09 | 学校法人慶應義塾 | がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤 |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
WO2018058489A1 (zh) * | 2016-09-30 | 2018-04-05 | 武汉华大吉诺因生物科技有限公司 | Cacna1h衍生的肿瘤抗原多肽及其应用 |
KR102145176B1 (ko) * | 2017-11-27 | 2020-08-18 | (주)프로스테믹스 | 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
CA3127871A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008501633A (ja) * | 2004-02-11 | 2008-01-24 | ユニバーシティ オブ ヴァージニア パテント ファウンデーション | 癌の診断及び治療のためのCav3アイソフォーム及びそのδ25スプライスバリアントの阻害 |
WO2010141842A2 (en) * | 2009-06-05 | 2010-12-09 | Krouse Andrew J | Interlaced method for treating cancer or a precancerous condition |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
SK109198A3 (en) | 1996-02-14 | 1999-06-11 | Isis Pharmaceuticals Inc | Sugar-modified gapped oligonucleotides |
US6251886B1 (en) * | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
JP4491240B2 (ja) | 2002-01-17 | 2010-06-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Igfbp−2およびigfbp−5を阻害する二重特異性アンチセンスオリゴヌクレオチド、並びにこれらの使用方法 |
US7662240B2 (en) * | 2004-06-22 | 2010-02-16 | The Timken Company | Seal for worm gear speed reducer |
KR100743255B1 (ko) * | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | T-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체 |
KR20090097188A (ko) * | 2006-12-19 | 2009-09-15 | 제넨테크, 인크. | 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 vegh-특이적 길항제 |
EP2190429B1 (en) * | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
CN104402998A (zh) * | 2008-07-08 | 2015-03-11 | 昂考梅德药品有限公司 | 分离的抗体 |
-
2012
- 2012-09-11 WO PCT/US2012/054567 patent/WO2013039859A1/en active Application Filing
- 2012-09-11 EP EP12832679.0A patent/EP2755674A4/en not_active Withdrawn
- 2012-09-11 SG SG10201601917XA patent/SG10201601917XA/en unknown
- 2012-09-11 CN CN201280055308.5A patent/CN103957923B/zh not_active Expired - Fee Related
- 2012-09-11 AU AU2012309800A patent/AU2012309800B2/en not_active Ceased
- 2012-09-11 JP JP2014529965A patent/JP2014526475A/ja active Pending
- 2012-09-11 MX MX2014002967A patent/MX2014002967A/es unknown
- 2012-09-11 SG SG11201400526TA patent/SG11201400526TA/en unknown
- 2012-09-11 CA CA2848311A patent/CA2848311A1/en not_active Abandoned
- 2012-09-11 US US13/609,942 patent/US20130064814A1/en not_active Abandoned
- 2012-09-11 KR KR1020147009726A patent/KR20140084034A/ko not_active Application Discontinuation
-
2014
- 2014-03-06 IL IL231385A patent/IL231385A0/en unknown
-
2015
- 2015-01-21 HK HK15100687.1A patent/HK1200120A1/xx unknown
-
2019
- 2019-11-15 US US16/685,279 patent/US20200197516A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008501633A (ja) * | 2004-02-11 | 2008-01-24 | ユニバーシティ オブ ヴァージニア パテント ファウンデーション | 癌の診断及び治療のためのCav3アイソフォーム及びそのδ25スプライスバリアントの阻害 |
WO2010141842A2 (en) * | 2009-06-05 | 2010-12-09 | Krouse Andrew J | Interlaced method for treating cancer or a precancerous condition |
Non-Patent Citations (5)
Title |
---|
HEO,J.H. ET AL.: "T-type Ca2+ channel blockers suppress the growth of human cancer cells.", BIOORG. MED. CHEM. LETT., vol. 18, no. 14, JPN6016020610, 15 July 2008 (2008-07-15), pages 3899 - 3901, XP022852859, DOI: doi:10.1016/j.bmcl.2008.06.034 * |
HUANG, Z. ET AL., PROTEIN CELL, vol. 1, no. 7, JPN6017037487, 2010, pages 638 - 55 * |
MULGREW,C.J. ET AL.: "Inhibition of human mesangial cell proliferation by targeting T-type calcium channels.", NEPHRON EXP. NEPHROL., vol. 113, no. 2, JPN6016020620, 11 August 2009 (2009-08-11), pages e77-e88 * |
SHAO,Y. ET AL.: "Expression of Voltage Sensitive Calcium Channel (VSCC) L-type Cav1.2(alpha1C) and T-type Cav3.2(alph", DEV. DYN., vol. 234, no. 1, JPN6016020617, September 2005 (2005-09-01), pages 54 - 62 * |
TAYLOR,J.T. ET AL.: "Selective blockade of T-type Ca2+ channels suppresses human breast cancer cell proliferation.", CANCER LETT., vol. 267, no. 1, JPN6016020613, 18 August 2008 (2008-08-18), pages 116 - 24, XP022797048, DOI: doi:10.1016/j.canlet.2008.03.032 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017195882A (ja) * | 2016-04-25 | 2017-11-02 | クラシエホールディングス株式会社 | 未分化細胞除去剤 |
Also Published As
Publication number | Publication date |
---|---|
US20200197516A1 (en) | 2020-06-25 |
AU2012309800B2 (en) | 2017-10-05 |
WO2013039859A1 (en) | 2013-03-21 |
EP2755674A1 (en) | 2014-07-23 |
US20130064814A1 (en) | 2013-03-14 |
HK1200120A1 (en) | 2015-07-31 |
AU2012309800A1 (en) | 2014-05-01 |
SG11201400526TA (en) | 2014-04-28 |
SG10201601917XA (en) | 2016-04-28 |
KR20140084034A (ko) | 2014-07-04 |
CN103957923B (zh) | 2018-05-25 |
IL231385A0 (en) | 2014-04-30 |
CN103957923A (zh) | 2014-07-30 |
MX2014002967A (es) | 2015-04-13 |
EP2755674A4 (en) | 2015-04-08 |
CA2848311A1 (en) | 2013-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200197516A1 (en) | Antagonists of Products of the HS.459642 Unigene Cluster for the Inhibition of Proliferation, Development or Differentiation of Stem Cells Including Cancer Stem Cells | |
JP2014526475A5 (ja) | ||
US20220033502A1 (en) | METHODS FOR UPREGULATING IMMUNE RESPONSES USING COMBINATIONS OF ANTI-RGMb AND ANTI-PD-1 AGENTS | |
JP6976855B2 (ja) | がん処置の治療有効性及びがん予後を予測するための方法及び組成物 | |
JP2008546387A (ja) | 癌を処置および診断するための組成物および方法 | |
CN114729040A (zh) | 抗tigit抗体 | |
WO2015003149A2 (en) | Soluble cd33 for treating myelodysplastic syndromes (mds) | |
US20140378531A1 (en) | Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors | |
EP2961853B1 (en) | Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers | |
US20210087247A1 (en) | Mps peptides and use thereof | |
EP1854473A1 (en) | Preventive/therapeutic agent for cancer | |
EP3700551A1 (en) | Cancer vaccine compositions and methods for using same to treat cancer | |
WO2010098166A1 (ja) | 細胞接着阻害剤およびその用途 | |
EP2958945B1 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
JP2013520169A (ja) | Mmsetを阻害するための組成物および方法 | |
US20160200804A1 (en) | Compositions and methods for treating anaplastic thyroid cancer | |
JP6029019B2 (ja) | 細胞接着阻害剤、細胞増殖阻害剤、並びに癌の検査方法および検査用キット | |
US20240083990A1 (en) | Novel stim1 splicing variants and uses thereof | |
JP2022513082A (ja) | 免疫応答を調節するためのIRE1α-XBP1シグナル伝達経路バイオマーカーの使用 | |
US20100086911A1 (en) | Preventive/therapeutic agent for cancer | |
BR112017018775B1 (pt) | Métodos e composições para previsão da eficácia terapêutica dos tratamentos e prognósticos de câncer | |
EP2732036A2 (en) | Compositions comprising agents that inhibit neuropilin and tolloid like 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150911 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150911 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160607 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160831 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170508 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20170515 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170711 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170814 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20171010 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180209 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180326 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20180420 |